

Contents

Chapter 1	Driving Successful Commercial Product Launches.....	1
	<i>Updated by Michael Reiner, MBA</i>	
Chapter 2	Development and Implementation of Regulatory Strategies for Medical Devices...	15
	<i>Updated by Thomas R. Hutchinson, MS, RAC, FRAPS</i>	
Chapter 3	Core Development Teams.....	21
	<i>Updated by Pamela J. Weagraff, MBA</i>	
Chapter 4	Components of Regulatory Strategy—The Basics	47
	<i>Updated by Melissa Walker, MS, RAC, FRAPS</i>	
Chapter 5	Setting up a Quality Management System	59
	<i>Updated by Abhishek Harde, PMP, RAC</i>	
Chapter 6	Risk Management Strategies for Device Design and Development Processes.....	93
	<i>Updated by Thomas McNamara, MSE, RAC</i>	
Chapter 7	Global Medical Device Labeling Strategies	111
	<i>Updated by Cathleen O’Connell, RPh, PhD</i>	
Chapter 8	Manufacturing	127
	<i>Updated by Andrea Armando, RAC</i>	
Chapter 9	Nonclinical Laboratory Testing	135
	<i>Updated by Dorota Grabowska, PhD and Peter A. Takes, PhD, RAC, FRAPS</i>	
Chapter 10	Global Medical Device Clinical Strategy	149
	<i>Updated by Dawn Norman, MS</i>	
Chapter 11	In Vitro Diagnostic Medical Devices	157
	<i>Updated by Jocelyn Jennings, MS, RAC</i>	
Chapter 12	Combination Products	171
	<i>Updated by Allyson B. Mullen and Jeffrey N. Gibbs</i>	

Chapter 13	Global Regulatory Processes.....	183
	<i>Updated by Xianjun (Catherine) Chen, MS, RAC, Manuel Urena and Brian Young</i>	
Chapter 14	Global Regulatory Process—Third-Party Point of View	205
	<i>Updated by Gert Bos, MSc, PhD, FRAPS</i>	
Chapter 15	Use of Standards in Medical Device Global Regulatory Strategy.....	217
	<i>Updated by Susumu Nozawa, RAC, FRAPS</i>	
Chapter 16	Global Medical Device Marketing Strategy.....	241
	<i>Updated by Charles Tam, MBA</i>	
Chapter 17	Regulatory Resources for Strategy Development.....	259
	<i>Updated by Gretchen E. Parker, PhD, RAC, CIP</i>	
Chapter 18	Global Postmarketing Regulatory Strategy	287
	<i>Updated by Scott D. Dickerhoff</i>	
Chapter 19	Borderline Regulation of Stem Cell Technologies: Therapies, Devices and Combination Products	305
	<i>Updated by Anu Gaur, PhD, MBA, MSRA, RAC</i>	
Chapter 20	Patents and Intellectual Property.....	321
	<i>Updated by Stanley F. Chalvire, Sean D. Detweiler, David A. Fazzolare and Lisa M. Warren</i>	
Chapter 21	Software	335
	<i>Updated by Koen Cobbaert, MSEE, MSRM</i>	
Chapter 22	Cybersecurity	361
	<i>Updated by Colin Morgan, CISSP, CISM, GPEN</i>	
Glossary	373
Index	389

Figures

Figure 1-1.	Reimbursement for Medical Devices.....	7
Figure 4-1.	Comparison of Target Market Release Timelines	56
Figure 5-1.	Basic Process Model.....	61
Figure 5-2.	PDCA Cycle in Resource Management	62
Figure 5-3.	Mandatory Procedures and Documents for ISO 13485:2003	69
Figure 5-4.	Implementing an ISO 13485:2016 QMS	71
Figure 5-5.	Sample Schedule for QMS Implementation	73
Figure 5-6.	QMS Documentation Defining Responsibilities.....	74
Figure 5-7.	Typical QMS Document Hierarchy	75
Figure 5-8.	Iterative PDCA Cycle.....	77
Figure 5-9.	ISO 17021 QMS Certification Cycle.....	79

Figure 5-10.	Design Process	85
Figure 6-1.	FDA's View on Managing Pre- and Postmarket Product Risks	101
Figure 6-2.	FDA's Role in Medical Product Risk Management (Rx Products)	102
Figure 6-3.	Framework for Environmental Health Risk Management	103
Figure 7-1.	Example of Label Incorporating a UDI	114
Figure 7-2.	Example of a Medical Device Label for Use in Multiple Regions.....	115
Figure 9-1.	Strategy for Performing Animal Studies	143
Figure 13-1.	Regulatory Submission Process Flow.....	183
Figure 13-2.	Data Integrity Verification Process Outline.....	189
Figure 15-1.	Document Hierarchy	223
Figure 16-1.	Estimated Cost of Medical Device Regulatory Approval by Country	247
Figure 21-1.	Details of Scrum Methodology	347
Figure 22-1.	Product Security Framework From the JSP	363
Figure 22-2.	AAMI TIR57 and ISO14971 Crosswalk.....	366

Tables

Table 1-1.	Main Types of US Reimbursement Coding Systems	9
Table 1-2.	Types of Economic Evaluations	11
Table 3-1.	Example—Development Phases	25
Table 3-2.	Regulatory Pathway Assessment Elements.....	28
Table 3-3.	Regulatory Strategy and Plan Elements	37
Table 3-4.	Ebb and Flow of Core Team Member Involvement	43
Table 4-1.	Simplified Global Regulatory Strategy Element Table.....	48
Table 4-2.	Simplified Example of the Expanded Element Table	54
Table 4-3.	Regulatory Submission Requirements	55
Table 4-4.	Summary of Regulatory Risks	57
Table 5-1.	Key Differences Between ISO 9001 and ISO 13485.....	59
Table 5-2.	Similarities Between ISO 9001 and ISO 13485.....	60
Table 5-3.	Comparison of ISO 13485:2003 and ISO 13485:2016	64
Table 5-4.	Applicability of ISO 13485 in Various Global Jurisdictions.....	70
Table 5-5.	Benefits and Barriers to Certification	78
Table 5-6.	Certification Body QMS Assessment Objectives, Scope and Criteria	80
Table 5-7.	Audit Duration for Medical Device ISO 13485 Audits Based on Staff Numbers ...	80
Table 5-8.	Factors That May Increase or Reduce Audit Durations.....	81
Table 6-1.	Risk Mitigation Strategies	95
Table 7-1.	Key Medical Device Labeling Regulations in the EU MDR.....	112
Table 7-2.	Key Medical Device Labeling Regulations in the US: Code of Federal Regulation	113
Table 7-3.	ISO FDIS 20417: Medical Devices—Information to be Supplied by the Manufacturer	116
Table 9-1.	The Universal Elements of GLP	137
Table 9-2.	Examples of GLP Violations From FDA Warning Letters	138
Table 9-3.	Sources of Device Risk.....	139
Table 9-4.	Biocompatibility Tests.....	140
Table 9-5.	Medical Device Classification Based on the Nature of Body Contact and Contact Duration	141
Table 9-6.	Basic Animal Study Protocol Elements	142
Table 9-7.	Animal Models for In Vivo Medical Device Assessment.....	144

Table 9-8.	International Animal Research Laws, Policies and Guidelines.....	144
Table 9-9.	Useful Web Resources for Planning and Conducting Animal Studies in Accordance With the Three Rs' Principles	145
Table 9-10.	Questions a Company Should Consider When Selecting a CRO.....	146
Table 13-1.	Global Submission Planning and Prioritization Process	187
Table 13-2.	Considerations for Selecting In-Country Agents	199
Table 16-1.	Example of a CV Medical Device Company Product Development Matrix	242
Table 16-2.	Country-Specific Information from the Handbook of Pharma and MedTech Compliance.....	249
Table 16-3.	High-Level Marketing and Advertising Information for Countries in Asia-Pacific.....	250
Table 16-4.	High-Level Marketing and Advertising Information for Countries in Europe.....	251
Table 16-5.	High-Level Marketing and Advertising Information for Countries in Latin America and South America.....	252
Table 17-1.	African and Middle Eastern Regulatory Agencies	264
Table 17-2.	Asia/Pacific Regulatory Agencies	266
Table 17-3.	European Commission Competent Authorities	268
Table 17-4.	Eastern European Agencies.....	270
Table 17-5.	Latin American Regulatory Agencies.....	272
Table 17-6.	North American Regulatory Agencies.....	273
Table 17-7.	Global Regulatory Professional Trade Organizations	274
Table 17-8.	Miscellaneous Resources	278
Table 17-9.	African/Middle Eastern Intelligence Resources	280
Table 17-10.	Asia/Pacific Intelligence Resources	280
Table 17-11.	European Commission Intelligence Resources.....	281
Table 17-12.	Latin American Intelligence Resources	282
Table 17-13.	North American and Other Critical Intelligence Resources	283
Table 19-1.	Summary of Select Revenue-Generating Cell Therapy Products Currently on the Market	306
Table 19-2.	Definitions of Manipulations Considered Minimal (US) or Not Substantial (EU)	307
Table 19-3.	Summary of Regulatory Routes and Documents Applicable to Stem Cell and/or Device Products	309